Achieve Life Sciences (ACHV) Change in Accured Expenses (2010 - 2026)

Achieve Life Sciences has disclosed Change in Accured Expenses across 17 years of filings, most recently posting $261000.0 for Q1 2026.

• Quarterly Change in Accured Expenses rose 112.65% year-over-year to $261000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 159.83% YoY) and the FY2025 annual result came in at -$1.1 million, down 254.75% from the prior year.
• Change in Accured Expenses rose to $261000.0 in Q1 2026, from -$510000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.7 million in Q2 2025 and troughed at -$2.1 million in Q1 2025.
• A 5-year average of $14058.8 and a median of $26000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 3516.67% — and 2023, when it soared 1692.31%.
• Tracing ACHV's Change in Accured Expenses over 5 years: stood at -$434000.0 in 2022, then surged by 240.78% to $611000.0 in 2023, then rose by 12.27% to $686000.0 in 2024, then tumbled by 174.34% to -$510000.0 in 2025, then soared by 151.18% to $261000.0 in 2026.
• Business Quant data shows ACHV's Change in Accured Expenses at $261000.0 in Q1 2026, -$510000.0 in Q4 2025, and -$1.2 million in Q3 2025.